Form 4: ANI Pharmaceuticals Executive Christopher Mutz Reports Stock Transaction
SEC Form 4 Filing
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.
Summary
- On February 29, 2024, Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reported a transaction.
- The transaction involved the withholding of 1,275 shares of common stock at a price of $67.67 per share for tax purposes.
- This was in connection with the vesting of 4,342 shares of restricted stock previously reported.
- Following the transaction, Mutz beneficially owns 92,387 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 7
Explanation: The document is a standard SEC filing related to stock transactions, indicating normal business operations. The sentiment is neutral to slightly positive as it reflects executive compensation and ownership.
Industry Context
This is a routine filing related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares withheld for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of stock transaction (shares withheld for tax purposes). |
| 03/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.